Table 2.

Characteristics of cases and controls in the common phase II set and the PLCO phase III data

“Common” phase II dataPhase III data
Cases (n = 160)BD controls (n = 160)GP controls (n = 480)Cases (n = 118)Controls (n = 474)
Center
 FCCC41 (25.6)11 (6.7)121 (25.2)
 FHCRC39 (24.4)39 (24.4)118 (24.6)
 Partners40 (25.0)110 (68.8)121 (25.2)
 MDACC40 (25.0)0 (0.0)120 (25.0)
Age
 30–5568 (42.5)73 (45.6)209 (44.8)0 (0.0)0 (0.0)
 55—5931 (19.4)26 (16.2)88 (18.9)14 (11.9)60 (12.7)
 60–6421 (13.1)28 (17.5)73 (15.7)37 (31.4)146 (30.8)
 ≥6540 (25.0)33 (20.6)96 (20.6)67 (56.8)268 (56.5)
Menopausal status
 Pre44 (30.6)43 (31.2)139 (36.7)0 (0.0)0 (0.0)
 Post100 (69.4)95 (68.8)240 (63.3)118 (100.0)474 (100.0)
Race
 White122 (76.2)127 (79.4)338 (73.2)106 (89.8)431 (90.9)
 Nonwhite38 (23.8)33 (20.6)124 (26.8)12 (10.2)43 (9.1)
Body mass index
 <2221 (18.3)24 (18.3)41 (20.5)22 (18.6)66 (14.0)
 22–24.932 (27.8)38 (29.0)59 (29.5)31 (26.3)113 (24.0)
 25–29.923 (20.0)38 (29.0)53 (26.5)37 (31.4)178 (37.9)
 ≥3039 (33.9)31 (23.7)47 (23.5)28 (23.7)113 (24.1)
Smoking
 Never68 (59.6)73 (55.7)176 (55.5)64 (54.2)291 (61.4)
 Former29 (25.4)40 (30.5)112 (35.3)46 (39.0)149 (31.4)
 Current17 (14.9)18 (13.7)29 (9.2)8 (6.8)34 (7.2)
Case characteristics
 Histology
 Serous88 (55.0)68 (57.6)
 Mucinous14 (8.8)2 (1.7)
 Endometrioid17 (10.6)14 (11.9)
 Clear cell9 (5.6)4 (3.4)
 Squamous cell1 (0.6)0 (0.0)
 Mixed epithelial23 (14.4)0 (0.0)
 Undifferentiated1 (0.6)2 (1.7)
 Other5 (3.1)3 (2.5)
 Adenocarcinoma NOS0 (0.0)22 (18.6)
 Unknown2 (1.2)0 (0.0)
 Granulosa cell0 (0.0)3 (2.5)
 Grade
 033 (20.6)
 111 (6.9)7 (5.9)
 211 (6.9)22 (18.6)
 3–485 (53.1)66 (55.9)
 Unknown20 (12.5)23 (19.5)
 Stage
 Early74 (46.2)32 (27.1)
 Late83 (51.9)84 (71.2)
 Unknown3 (1.9)2 (1.7)